Cidara Therapeutics (CDTX) Expected to Announce Earnings on Thursday

Cidara Therapeutics (NASDAQ:CDTX) is expected to issue its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect Cidara Therapeutics to post earnings of ($1.24) per share for the quarter. Investors can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, November 6, 2025 at 5:00 PM ET.

Cidara Therapeutics (NASDAQ:CDTX) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.65) EPS for the quarter, topping analysts’ consensus estimates of ($1.87) by $0.22. On average, analysts expect Cidara Therapeutics to post $-9 EPS for the current fiscal year and $-14 EPS for the next fiscal year.

Cidara Therapeutics Stock Performance

Shares of CDTX opened at $102.73 on Tuesday. The stock has a 50 day simple moving average of $86.40 and a 200 day simple moving average of $56.29. Cidara Therapeutics has a 52-week low of $12.74 and a 52-week high of $121.21. The firm has a market capitalization of $2.61 billion, a PE ratio of -9.23 and a beta of 1.32.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on CDTX shares. Citigroup restated a “market outperform” rating on shares of Cidara Therapeutics in a report on Tuesday, October 21st. Guggenheim set a $167.00 price target on Cidara Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, September 24th. JMP Securities set a $173.00 price objective on shares of Cidara Therapeutics and gave the stock a “market outperform” rating in a research report on Friday, October 3rd. JPMorgan Chase & Co. initiated coverage on shares of Cidara Therapeutics in a research note on Friday, October 10th. They set an “overweight” rating and a $200.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cidara Therapeutics in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Cidara Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $151.33.

Insider Activity at Cidara Therapeutics

In related news, insider Nicole Negar Davarpanah sold 474 shares of the business’s stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $62.86, for a total value of $29,795.64. Following the sale, the insider owned 31,418 shares of the company’s stock, valued at $1,974,935.48. The trade was a 1.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 7.64% of the company’s stock.

Hedge Funds Weigh In On Cidara Therapeutics

A number of hedge funds have recently made changes to their positions in CDTX. California State Teachers Retirement System bought a new stake in Cidara Therapeutics in the second quarter valued at approximately $51,000. Legal & General Group Plc acquired a new position in Cidara Therapeutics in the second quarter valued at $73,000. Tower Research Capital LLC TRC boosted its position in Cidara Therapeutics by 66.8% during the second quarter. Tower Research Capital LLC TRC now owns 1,556 shares of the biotechnology company’s stock valued at $76,000 after acquiring an additional 623 shares during the last quarter. BNP Paribas Financial Markets boosted its position in shares of Cidara Therapeutics by 10,594.1% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,818 shares of the biotechnology company’s stock valued at $89,000 after purchasing an additional 1,801 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Cidara Therapeutics during the 2nd quarter worth approximately $146,000. 35.82% of the stock is currently owned by institutional investors.

About Cidara Therapeutics

Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.